In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Mochi Health, one of those implicated, is one of the largest telehealth providers of compounded GLP-1RAs. Eli Lilly maintains ...

According to a CNBC report, the company filed lawsuits against Mochi Health, Fella Health, Willow Health, and Henry Med on ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

In April 2025, Eli Lilly filed lawsuits against two compounding pharmacies—Strive Pharmacy and Empower Clinic Services—alleging that they were selling unapproved versions of tirzepatide.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

Compounding pharmacies use active pharmaceutical ingredients – the part of the medication that produces therapeutic effects – ...

Ore Huiying / Bloomberg / Getty Images Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.